We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Specific Blood Test Diagnoses Early Onset Kidney Failure

By LabMedica International staff writers
Posted on 16 Sep 2014
Print article
ARKRAY\'s SPOTCHEM Banalyst CysC kit for the measurement of Cystatin C
The SPOTCHEM Banalyst CysC kit for the measurement of Cystatin C (Photo courtesy of ARKRAY, INC.)
A new and dedicated reagent for the measurement of cystatin C on a portable centrifuge-method clinical chemistry analyzer has been released.

The blood test will support the diagnosis and treatment of early onset kidney failure within clinics where the fully automatic, simple and fast measurement of cystatin C can be used in clinics to aid in rapid testing.

Cystatin C is an important indicator of kidney function. Its utility as an accurate diagnostic marker of diabetic nephropathy, immunoglobulin A (IgA) nephropathy, other types of chronic kidney disease (CKD) and early onset kidney damage is well documented.

In the past, serum creatinine has been used as test for kidney function but this is subject to influence from diet, muscle mass, and exercise. In contrast, cystatin C is not affected by these factors and rises in concentration within blood in line with even minor decreases in kidney function. This allows it to be used for the diagnosis of early onset kidney failure which serum creatinine cannot detect.

The SPOTCHEM Banalyst CysC (Cystatin C) from ARKRAY Inc. (Kyoto, Japan) is an in vitro diagnostic product for the testing of kidney failure. It is used together with whole blood or plasma samples on the SPOTCHEM Banalyst SI-3610, which is being sold through ARKRAY Inc. The SPOTCHEM Banalyst SI-3610 uses Micro Total Analysis Systems (µ-TAS) technology to offer high precision measurement in a compact test system. The µ-TAS analysis system uses a microprocessed chip to include flow channels and reactions which then allows separation of blood cells, reagent mixing and other processes in a short space of time. CysC is the fourth reagent in the series joining glycosylated hemoglobin (HbA1c), C-reactive protein (CRP) and other diabetes and infectious diseases biomarkers.

Related Links:

ARKRAY Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.